Table 1.
Patient’s clinic and paraclinic features of the first (post-COVID-19 GBS) and of the second event (post-COVID-19 vaccine GBS recurrence).
| GBS type |
CSF analysis | Ganglioside antibodies (IgM) | Additional features | Therapy | Disability scales | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ly (/µL)* |
Prot (g/L)^ |
Cranial nerve | Autonomic dysfunction | MRC-MS (T0; T1) |
GBS-DS (T0; T1) |
|||||
| 1st event | AIDP | 2 | 0.58 | GD1b | yes | yes | IVIg | 24; 60 | 4; 0 | |
| 2nd event | AIDP | <2 | 0.81 | GM3/4, GD1a/b, GT1b | no | no | IVIg | 54; 60 | 3; 0 | |
GBS, Guillain-Barré syndrome; CSF, cerebrospinal fluid; Ly, lymphomonocytes; *reference range, < 5; Prot, total proteins; ^reference range, < 0.52; MRC-MS, Medical Research Council Muscle Score; GBS-DS, Guillain Barré Syndrome Disability Score; AIDP, Acute Inflammatory Demyelinating Polyneuropathy; IVIg, intravenous immunoglobulins; T0, neurological evaluation at onset; T1, neurological evaluation at 3-month follow-up.